Northland Capital Markets Maintains Outperform on Cardlytics, Lowers Price Target to $7
Northland Capital Markets Maintains Outperform on Cardlytics, Lowers Price Target to $7
北國資本市場維持對Cardlytics的跑贏大盤評級，將目標股價下調至7美元。
Northland Capital Markets analyst Luke Horton maintains Cardlytics (NASDAQ:CDLX) with a Outperform and lowers the price target from $14 to $7.
北陸資本市場分析師盧克·霍頓認爲Cardlytics（NASDAQ：CDLX）表現良好，並將價格目標從14美元降至7美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。